Ku Shen

Presentation Slides

Chinese Medicine Research Hub

Meta-Analysis

Adding Compound Kushen Injection (CKI), a traditional Chinese medicine, to chemotherapy treatment enhanced treatment response and reduced side effects in advanced colorectal cancer patients.

2024 Integrative Cancer Therapies Efficacy and Safety of Compound Kushen Injection for Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials with Trial Sequential Analysis
Wu J, Ma X, Wang X, Zhu G, Wang H, Zhang Y, Li J

Executive Summary

Write an executive summary in the form of a blog article on the topic of "Research into Chinese medicine treatment for Ku Shen" summarising the research below and using language that can be easily understood by patients and avoiding medical jargon using a professional and caring tone of voice.

Write an executive summary in the form of a blog article on the topic of "Researched Chinese medicine treatments for Ku Shen" summarising the research below in an objective and easy to understand way, and using language that can be easily understood by patients. Group the article into Chinese medicine treatments first, followed by nutrition and other treatments. Avoid using medical jargon and use a professional and caring tone of voice.

Write me a concise but easy to understand executive summary on the topic of "Chinese medicine treatments for Ku Shen" based on the following research that I will give you. Your summary should be 2 paragraphs long in Australian English spelling and include references to the studies.

A Meta-Analysis published in 2024 in the journal Integrative Cancer Therapies found that Adding Compound Kushen Injection (CKI), a traditional Chinese medicine, to chemotherapy treatment enhanced treatment response and reduced side effects in advanced colorectal cancer patients. This study systematically collected data from a myriad of sources including, but not limited to, PubMed, the Cochrane Library, and ClinicalTrials.gov up to April 20, 2024. An assessment tool, ROB2, was used to measure the quality of the included trials, while data analysis was done using Stata 16. Publication bias was evaluated with the funnel plot and Egger's test. To calculate the final required sample size in this meta-analysis and verify whether the results presented a stable conclusion, trial sequential analysis was used. The data collected from these sixteen trials, consisting of 1378 patients showcased that when compared to chemotherapy alone, the combination of CKI and chemotherapy resulted in improved response rates and enhancement of the patient's performance status. Furthermore, this combination therapy was associated with fewer adverse reactions like leukopenia, thrombocytopenia, gastrointestinal reactions, and liver damage. Patients also exhibited high CD4 ratios and comparatively low CD8 T cell ratios. A subgroup analysis further demonstrated that the response rates improved significantly when CKI was combined with specific chemotherapy regimens. Overall, this data strongly suggests that the addition of CKI to chemotherapy provided statistically significant and clinically relevant improvements in treatment response rates, patient wellbeing, reduction in adverse reactions, and enhanced immune function.

Moderation Tools

Topic